Phase 3 trials (Frias et al., 2021
Two entirely separate timelines
Research has shown potential benefits for tendon and ligament repair, muscle recovery, gastrointestinal conditions such as leaky gut and inflammatory bowel issues, and even neuroprotective effects
As US patent exclusivity approaches its 2028 expiration, key dynamics to watch include potential label expansions (such as additional GVHD or inflammatory indications), intensifying competition from next-generation JAK inhibitors and Incytes ability to sustain patient demand while adapting to pricing reforms
Its the first FDAapproved oral GLP1 for weight loss This is a major milestone in the weightmanagement category
Many subset estimates may have large standard errors, meaning that even large differences between groups may not be statistically significant